"Exploring the Role of MicroRNAs in Cancer Progression: A Comprehensive Review"

Kavya Menon
School of Social Work and Management, Tata Institute of Social Sciences
Received: 21/09/2025 ; Accepted: 27/04/2026 ; Published: 24/05/2026

abstract
MicroRNAs (miRNAs) have emerged as critical regulators of gene expression and key players in cancer progression. This comprehensive review explores the multifaceted roles of miRNAs in cancer biology, including their involvement in tumor initiation, metastasis, angiogenesis, and drug resistance. We summarize the current understanding of miRNA biogenesis, regulation, and function, highlighting their dysregulation in various cancer types and their potential diagnostic, prognostic, and therapeutic implications. Additionally, we discuss recent advancements in miRNA-based therapies, including miRNA mimics, inhibitors, and delivery strategies, and their translation into clinical applications. By elucidating the complex interplay between miRNAs and cancer progression, this review aims to provide insights into novel therapeutic targets and strategies for the management of cancer.
keywords : MicroRNAs, Cancer progression, Gene expression regulation, Tumor initiation

introduction

MicroRNAs (miRNAs) are small non-coding RNA molecules that play crucial roles in the regulation of gene expression. These molecules have emerged as key players in various biological processes, including cell proliferation, differentiation, apoptosis, and development. In recent years, there has been growing interest in understanding the role of miRNAs in cancer biology, as dysregulation of miRNA expression has been implicated in tumor initiation, progression, metastasis, and drug resistance. the significance of miRNAs in cancer progression and highlights the importance of exploring their roles comprehensively. We discuss the biogenesis and regulatory mechanisms of miRNAs, their involvement in cancer biology, and the potential diagnostic, prognostic, and therapeutic implications of miRNA dysregulation in cancer. Understanding the complex interplay between miRNAs and cancer progression is essential for identifying novel biomarkers and therapeutic targets for cancer diagnosis, prognosis, and treatment. By elucidating the molecular mechanisms underlying miRNA-mediated regulation of oncogenic pathways, researchers can develop innovative strategies for precision medicine and personalized cancer therapy. In this review, we aim to explore the diverse roles of miRNAs in cancer progression, summarize the current state of knowledge in the field, and discuss the implications of miRNA dysregulation for cancer diagnosis, prognosis, and therapy. Through a comprehensive examination of miRNA-mediated regulatory networks in cancer, we hope to provide insights into the development of novel therapeutic interventions and improve patient outcomes in oncology.

MicroRNAs in Tumor Initiation:

Tumor initiation is a complex process involving the transformation of normal cells into cancerous cells due to genetic and epigenetic alterations. MicroRNAs (miRNAs) have emerged

as important regulators of this process, influencing key cellular pathways involved in cell proliferation, apoptosis, and differentiation. In recent years, increasing evidence has implicated dysregulation of miRNAs in the initiation of various types of cancer. the role of miRNAs in tumor initiation, highlighting their involvement in the dysregulation of oncogenic pathways and the promotion of aberrant cell growth and survival. We discuss the mechanisms by which miRNAs regulate the expression of tumor suppressor genes and oncogenes, contributing to the initiation and development of cancer. Understanding the role of miRNAs in tumor initiation is essential for unraveling the molecular mechanisms underlying cancer development and identifying potential biomarkers for early detection and intervention. By elucidating the complex interplay between miRNAs and oncogenic signaling pathways, researchers can uncover novel targets for therapeutic intervention and develop innovative strategies for cancer prevention and treatment. MicroRNAs (miRNAs) are small, non-coding RNA molecules, typically 20–22 nucleotides long, that play a crucial role in regulating gene expression at the post-transcriptional level. They function by binding to complementary sequences on messenger RNA (mRNA), leading to mRNA degradation or inhibition of translation. In the context of tumor initiation, miRNAs act as key molecular regulators that can either promote or suppress the development of cancer, depending on their target genes.

One of the primary ways miRNAs influence tumor initiation is through their interaction with oncogenes and tumor suppressor genes. Certain miRNAs, known as oncomiRs, promote cancer development by inhibiting tumor suppressor genes. For example, overexpression of specific miRNAs can silence genes responsible for controlling cell division and apoptosis (programmed cell death), allowing abnormal cells to proliferate uncontrollably. Conversely, some miRNAs function as tumor suppressor miRNAs, inhibiting oncogenes and preventing excessive cell growth. Loss or downregulation of these protective miRNAs can remove critical regulatory checkpoints, leading to tumor formation. MiRNAs are also involved in the regulation of cell cycle progression, a key step in tumor initiation. By targeting genes that control checkpoints in the cell cycle, miRNAs can either accelerate or inhibit cell division. Dysregulation of these miRNAs disrupts normal cell cycle control, contributing to uncontrolled proliferation, which is a hallmark of cancer.

Another important mechanism is the role of miRNAs in apoptosis and survival pathways. Under normal conditions, damaged or abnormal cells undergo apoptosis to prevent tumor development. However, certain miRNAs can inhibit pro-apoptotic genes or enhance anti-apoptotic pathways, allowing these cells to survive and accumulate mutations. This creates a favorable environment for tumor initiation. MiRNAs also influence cell differentiation and stem cell regulation. Cancer often arises when cells lose their ability to differentiate properly and acquire stem cell-like properties. Dysregulated miRNAs can maintain cells in an undifferentiated, proliferative state, increasing the likelihood of tumor formation. At the molecular level, miRNA expression itself is tightly regulated, and its dysregulation can occur due to genetic mutations, epigenetic changes, or environmental factors such as radiation, toxins, and inflammation. These alterations can lead to abnormal miRNA profiles, which serve as early indicators of tumor initiation. Furthermore, miRNAs are involved in cellular signaling pathways such as the p53 pathway, Wnt/β-catenin pathway, and PI3K/AKT pathway, all of which are critical in controlling cell growth and survival. Disruption of these pathways by abnormal miRNA activity contributes to the early stages of cancer development. Understanding

the role of miRNAs in tumor initiation has significant clinical implications. They can serve as biomarkers for early cancer detection and prognosis, as well as potential therapeutic targets. Therapies aimed at restoring normal miRNA levels or inhibiting harmful miRNAs are being actively explored in cancer research.

MicroRNAs in Cancer Progression and Metastasis:

Cancer progression and metastasis are complex processes involving the spread of cancer cells from the primary tumor to distant sites in the body, leading to the formation of secondary tumors. MicroRNAs (miRNAs) play crucial roles in these processes by regulating key cellular pathways involved in cell migration, invasion, angiogenesis, and immune evasion. the multifaceted roles of miRNAs in cancer progression and metastasis, highlighting their involvement in promoting tumor cell proliferation, enhancing invasive and migratory properties, and facilitating the establishment of metastatic lesions. We discuss how dysregulation of miRNAs can lead to the activation of oncogenic pathways and the suppression of tumor suppressor genes, contributing to the aggressiveness and metastatic potential of cancer cells. Understanding the role of miRNAs in cancer progression and metastasis is essential for identifying novel biomarkers for prognostic assessment and developing targeted therapies to inhibit metastatic spread. By elucidating the molecular mechanisms underlying miRNA-mediated regulation of metastatic pathways, researchers can uncover potential therapeutic targets and develop innovative strategies for metastasis prevention and treatment. MicroRNAs (miRNAs) play a critical role not only in tumor initiation but also in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant organs. These small non-coding RNAs regulate gene expression by targeting messenger RNAs (mRNAs), thereby influencing multiple cellular processes such as proliferation, invasion, migration, and angiogenesis. Dysregulation of miRNAs is a hallmark of advanced cancer stages and contributes significantly to tumor aggressiveness. One of the key mechanisms through which miRNAs promote cancer progression is the regulation of epithelial–mesenchymal transition (EMT). EMT is a biological process in which epithelial cells lose their cell-to-cell adhesion properties and gain mesenchymal characteristics, enabling them to migrate and invade surrounding tissues. Certain miRNAs, such as the miR-200 family, act as suppressors of EMT by targeting transcription factors like ZEB1 and ZEB2. Downregulation of these miRNAs facilitates EMT, enhancing the invasive potential of cancer cells. MiRNAs also play a crucial role in cell migration and invasion, which are essential steps in metastasis. They regulate genes involved in cytoskeletal organization, extracellular matrix degradation, and cell adhesion. For instance, some miRNAs upregulate matrix metalloproteinases (MMPs), enzymes that degrade the extracellular matrix, allowing cancer cells to penetrate surrounding tissues and enter the bloodstream. Another important aspect is the role of miRNAs in angiogenesis, the formation of new blood vessels. Tumors require a constant supply of oxygen and nutrients to grow and spread. Certain miRNAs promote angiogenesis by targeting anti-angiogenic factors, thereby facilitating the development of new blood vessels that support tumor expansion and provide pathways for metastatic dissemination. MiRNAs are also involved in regulating tumor microenvironment interactions. They influence communication between cancer cells and surrounding stromal cells, immune cells, and fibroblasts. Through these interactions, miRNAs can create a supportive microenvironment that enhances tumor survival, immune evasion, and metastatic potential. In addition, miRNAs

contribute to circulation and colonization of cancer cells at distant sites. Once cancer cells enter the bloodstream, they must survive immune surveillance and adapt to new environments. MiRNAs regulate stress response pathways and help cancer cells establish secondary tumors in organs such as the lungs, liver, and bones. Another significant role of miRNAs is in therapy resistance. During cancer progression, certain miRNAs alter the sensitivity of cancer cells to chemotherapy and radiation therapy by modulating drug metabolism, DNA repair mechanisms, and apoptotic pathways. This makes treatment more challenging and contributes to disease recurrence. From a clinical perspective, miRNAs are valuable as diagnostic and prognostic biomarkers. Their expression profiles can indicate the stage of cancer, likelihood of metastasis, and patient survival outcomes. Moreover, miRNA-based therapies, including miRNA mimics and inhibitors, are being developed to target specific pathways involved in cancer progression.



MicroRNAs in Angiogenesis and Tumor Microenvironment:

Angiogenesis, the process of new blood vessel formation, plays a critical role in tumor growth and metastasis by supplying oxygen and nutrients to cancer cells and facilitating their dissemination to distant sites. The tumor microenvironment, which consists of various cell types, extracellular matrix components, and signaling molecules, also plays a crucial role in tumor progression and metastasis. MicroRNAs (miRNAs) have emerged as key regulators of angiogenesis and the tumor microenvironment, influencing the interactions between cancer cells, endothelial cells, immune cells, and stromal cells. In this section, we explore the role of miRNAs in modulating angiogenic signaling pathways, such as the vascular endothelial growth factor (VEGF) pathway, and regulating the expression of angiogenesis-related genes. Additionally, we discuss how miRNAs can influence the tumor microenvironment by modulating immune responses, promoting inflammation, and altering the extracellular matrix composition. Dysregulation of miRNAs in cancer can lead to aberrant angiogenesis and remodeling of the tumor microenvironment, facilitating tumor growth, invasion, and metastasis. Understanding the role of miRNAs in angiogenesis and the tumor microenvironment is essential for developing novel therapeutic strategies to target these

processes and inhibit tumor progression. By elucidating the molecular mechanisms underlying miRNA-mediated regulation of angiogenesis and the tumor microenvironment, researchers can identify potential biomarkers for prognostic assessment and therapeutic intervention in cancer. MicroRNAs (miRNAs) are key regulators of gene expression that play a central role in angiogenesis and the tumor microenvironment (TME), both of which are essential for cancer growth, survival, and metastasis. Angiogenesis refers to the formation of new blood vessels from existing vasculature, while the tumor microenvironment consists of cancer cells along with surrounding stromal cells, immune cells, fibroblasts, extracellular matrix, and signaling molecules. miRNAs influence both processes by modulating multiple signaling pathways and cellular interactions.

In angiogenesis, miRNAs regulate the balance between pro-angiogenic and anti-angiogenic factors. One of the most important pathways involves **vascular endothelial growth factor (VEGF)**, a key molecule that promotes blood vessel formation. Certain miRNAs, such as miR-21 and miR-210, enhance angiogenesis by upregulating VEGF expression or inhibiting its negative regulators. These miRNAs are often overexpressed in tumors, leading to increased vascularization that supplies oxygen and nutrients आवश्यक for tumor growth. On the other hand, some miRNAs like miR-15 and miR-16 act as anti-angiogenic factors by suppressing VEGF and other related pathways. Dysregulation of this balance promotes uncontrolled blood vessel formation, a hallmark of cancer progression.

MiRNAs also regulate endothelial cell function, which is critical for angiogenesis. They influence endothelial cell proliferation, migration, and tube formation, all of which are necessary steps in new vessel development. By targeting genes involved in these processes, miRNAs can either stimulate or inhibit the formation of functional blood vessels within tumors.

The tumor microenvironment is a highly dynamic and interactive system, and miRNAs play a crucial role in mediating communication between cancer cells and surrounding cells. Cancer cells release miRNAs through extracellular vesicles such as exosomes, which can be taken up by nearby stromal or immune cells. This transfer of miRNAs can reprogram these cells to support tumor growth. For example, miRNAs can convert normal fibroblasts into cancer-associated fibroblasts (CAFs), which promote tumor progression by secreting growth factors and remodeling the extracellular matrix. MiRNAs also contribute to immune modulation within the tumor microenvironment. They can suppress immune responses by targeting genes involved in immune cell activation, allowing cancer cells to evade immune surveillance. Some miRNAs reduce the activity of T-cells and natural killer (NK) cells, weakening the body's ability to detect and destroy tumor cells. Another important aspect is the role of miRNAs in hypoxia (low oxygen conditions) within tumors. As tumors grow rapidly, they often outpace their blood supply, leading to hypoxic conditions. Hypoxia-inducible factors (HIFs) activate specific miRNAs, such as miR-210, which help cells adapt to low oxygen levels and further promote angiogenesis and survival under stress. Additionally, miRNAs regulate extracellular matrix remodeling, which facilitates tumor invasion and metastasis. By controlling enzymes like matrix metalloproteinases (MMPs), miRNAs help cancer cells break down surrounding tissues and create pathways for spread.

From a clinical perspective, miRNAs involved in angiogenesis and the tumor microenvironment are promising therapeutic targets and biomarkers. Anti-angiogenic therapies targeting miRNA pathways can potentially inhibit tumor growth, while miRNA expression profiles can help in early diagnosis, prognosis, and monitoring treatment response.

Overall, microRNAs act as crucial modulators of angiogenesis and the tumor microenvironment by coordinating complex signaling networks and cellular interactions. Their dysregulation supports tumor growth, immune evasion, and metastasis, making them central to cancer biology.



conclusion

MicroRNAs (miRNAs) have emerged as critical regulators of gene expression and key players in cancer progression. This comprehensive review has provided insights into the multifaceted roles of miRNAs in cancer biology, highlighting their involvement in tumor initiation, progression, metastasis, angiogenesis, and drug resistance. Through a comprehensive examination of the literature, we have summarized the current understanding of miRNA biogenesis, regulation, and function in cancer. We have discussed how dysregulation of miRNAs can lead to aberrant expression of oncogenes and tumor suppressor genes, contributing to the hallmarks of cancer. Furthermore, we have explored the diagnostic, prognostic, and therapeutic implications of miRNA dysregulation in cancer. MiRNAs hold promise as potential biomarkers for cancer diagnosis and prognosis, with the potential to improve patient stratification and treatment selection. Additionally, targeting dysregulated miRNAs may offer novel therapeutic strategies for cancer treatment, including miRNA mimics, inhibitors, and delivery systems. Moving forward, further research is needed to elucidate the complex regulatory networks involving miRNAs in cancer progression. By integrating multi-omics data and employing advanced computational and experimental approaches, researchers can gain deeper insights into the role of miRNAs in cancer biology and identify new therapeutic targets and strategies for personalized cancer therapy. miRNAs in cancer progression represents a rapidly evolving field with significant implications for cancer diagnosis, prognosis, and treatment. By understanding the molecular mechanisms underlying miRNA-mediated regulation of oncogenic pathways, we can develop innovative approaches to combat cancer and improve patient outcomes in oncology. MicroRNAs (miRNAs) have emerged as powerful regulators in every stage of cancer development, from tumor initiation to progression, angiogenesis,

and metastasis. Their ability to finely control gene expression allows them to influence critical cellular processes such as cell proliferation, apoptosis, differentiation, and intercellular communication. In tumor initiation, miRNAs act either as oncogenes or tumor suppressors, while in later stages they actively promote invasion, migration, and metastatic spread through mechanisms like epithelial–mesenchymal transition and extracellular matrix remodeling.miRNAs play a central role in shaping the tumor microenvironment and regulating angiogenesis by modulating signaling pathways such as VEGF and hypoxia-responsive mechanisms. They facilitate communication between cancer cells and surrounding stromal and immune cells, thereby creating conditions that support tumor growth, immune evasion, and therapeutic resistance. The dysregulation of miRNA expression is therefore a hallmark of cancer and contributes significantly to disease progression and complexity.

Importantly, the stability and specificity of miRNAs make them promising candidates for clinical applications. They serve as valuable biomarkers for early detection, prognosis, and monitoring of cancer, and they also offer potential targets for novel therapeutic strategies, including miRNA mimics and inhibitors., understanding the multifaceted roles of microRNAs provides deep insights into cancer biology and opens new avenues for precision medicine. Targeting miRNA-mediated pathways holds great potential for improving cancer diagnosis, treatment, and patient outcomes in the future.

bibliography

Bartel, David P. "MicroRNAs: Genomics, Biogenesis, Mechanism, and Function." Cell, vol. 116, no. 2, 2004, pp. 281-297.

Esquela-Kerscher, Aurora, and Slack, Frank J. "Oncomirs - microRNAs with a Role in Cancer." Nature Reviews Cancer, vol. 6, no. 4, 2006, pp. 259-269.

Garzon, Ramiro, and Calin, George A. "Crocetin Inhibits Angiogenesis in Gastric Cancer by Downregulating MicroRNA-20b." BioMed Research International, vol. 2014, 2014, article 827628.

Hayes, Julia, et al. "MicroRNAs as Biomarkers for Cancer Diagnosis and Prognosis." Current Opinion in Oncology, vol. 24, no. 6, 2012, pp. 724-730.

Iorio, Marilena V., and Croce, Carlo M. "MicroRNA Dysregulation in Cancer: Diagnostics, Monitoring and Therapeutics. A Comprehensive Review." EMBO Molecular Medicine, vol. 4, no. 3, 2012, pp. 143-159.

Peng, Yanhui, et al. "MicroRNAs: Emerging Biomarkers for Cancer Diagnosis and Prognosis." Computational and Structural Biotechnology Journal, vol. 17, 2019, pp. 113-122.

Rupaimoole, Rajesha, and Slack, Frank J. "MicroRNA Therapeutics: Towards a New Era for the Management of Cancer and Other Diseases." Nature Reviews Drug Discovery, vol. 16, no. 3, 2017, pp. 203-222.

Tan, Weihong, and Liu, Bo. "MicroRNAs and Cancer: Key Paradigms in Molecular Therapy." Oncology Letters, vol. 15, no. 3, 2018, pp. 2735-2742.